December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

364.04 -32.28 (-8.14%)
Delayed Quote Updated: 10:52 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Madrigal (MDGL) Q3 2026 Earnings Call Transcript ↗
Rezdiffra hits blockbuster status as net income turns positive for first time. 
Via The Motley Fool
Topics Earnings
News headline image
What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Call ↗
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported third-quarter 2026 net sales of $431.3 million for its MASH treatment Rezdiffra, up 50% from the prior-year period, as the company said it continued to... 
Via MarketBeat
Topics Earnings
News headline image
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? ↗
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease. 
Via The Motley Fool
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Q2 Beat Yet Shares Slide on Rezdiffra Ramp Worries ↗
Via Chartmill
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growth ↗
Via Chartmill
Topics Earnings
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Reports Q4 2025 Revenue Beat and Significant EPS Miss ↗
Via Chartmill
News headline image
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off ↗
Rezdiffra's biggest growth opportunity may still be ahead. 
Via The Motley Fool
News headline image
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands ↗
Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH... 
Via MarketBeat
News headline image
Madrigal Pharmaceuticals Q2 Earnings Call Highlights ↗
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients... 
Via MarketBeat
Topics Earnings
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
Sometimes, little-known stocks are worth buying. 
Via The Motley Fool
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo ↗
Via Stocktwits
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
All three could become highly prominent biotech companies within 10 years. 
Via The Motley Fool
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
News headline image
Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗
Arrowhead (ARWR) Q2 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Madrigal (MDGL) Q1 2026 Earnings Transcript ↗
Madrigal (MDGL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
These companies boast significant upside potential. 
Via The Motley Fool
News headline image
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
The next 10 months might be challenging for this biotech. 
Via The Motley Fool
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Under-the-Radar Stocks to Buy and Hold ↗
These biotechs are slowly making a name for themselves. 
Via The Motley Fool
News headline image
Madrigal (MDGL) Q4 2025 Earnings Call Transcript ↗
Madrigal (MDGL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
Via The Motley Fool
News headline image
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday ↗
The stock has had quite the run following Rezdiffra's 2024 approval by the FDA. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.